Adverse events at six months v 24 months. Data are shown as No (%)
| Leflunomide | Sulfasalazine | ||||||
|---|---|---|---|---|---|---|---|
| 0–6 Months (n=133) | 12–24 Months (n=60) | 0–6 Months (n=133) | 12–24 Months (n=60) | ||||
| Diarrhoea | 23 (17) | 1 (2) | 12 (9) | 5 (8) | |||
| Nausea | 13 (10) | 0 (0) | 23 (17) | 4 (7) | |||
| Alopecia | 10 (8) | 3 (5) | 7 (5) | 0 (0) | |||
| Headache | 9 (7) | 1 (2) | 14 (11) | 0 (0) | |||
| Hypertension | 8 (6) | 3 (5) | 5 (4) | 2 (3) | |||
| Pruritus | 7 (5) | 1 (2) | 4 (3) | 2 (3) | |||
| Gastrointestinal pain | 6 (5) | 3 (5) | 8 (6) | 2 (3) | |||